KL-1333
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 555598

CAS#: 1800405-30-4

Description: KL1333 is an orally available, small organic molecule that reacts with NAD(P)H:quinone oxidoreductase 1 (NQO1) as a substrate, resulting in increases in intracellular NAD+ levels via NADH oxidation. KL-1333 Improves Energy Metabolism and Mitochondrial Dysfunction in MELAS Fibroblasts.


Price and Availability

Size
Price

200mg
USD 2250
2g
USD 7950
Size
Price

500mg
USD 3650
Size
Price

1g
USD 4650

KL-1333, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received..


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 555598
Name: KL-1333
CAS#: 1800405-30-4
Chemical Formula: C14H12N2O2
Exact Mass: 240.0899
Molecular Weight: 240.262
Elemental Analysis: C, 69.99; H, 5.03; N, 11.66; O, 13.32


Synonym: KL-1333; KL 1333; KL1333;

IUPAC/Chemical Name: 2-(1-Methylethyl)-3H-naphth(1,2-d)imidazole-4,5-dione

InChi Key: AJFWITSBVLLDCC-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H12N2O2/c1-7(2)14-15-10-8-5-3-4-6-9(8)12(17)13(18)11(10)16-14/h3-7H,1-2H3,(H,15,16)

SMILES Code: O=C(C1=C2N=C(C(C)C)N1)C(C3=C2C=CC=C3)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.90.01


Additional Information

Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), one of the most common maternally inherited mitochondrial diseases, is caused by mitochondrial DNA mutations that lead to mitochondrial dysfunction. Several treatment options exist, including supplementation with CoQ10, vitamins, and nutrients, but no treatment with proven efficacy is currently available.